Catalent completes acquisition of Australia's Pharmapak
US-based Catalent Pharma Solutions has strengthened its ability to provide integrated solutions to customers with the acquisition of Pharmapak Technologies, an Australian pharmaceutical packaging business.
The deal provides regional packaging capabilities and complements Catalent's existing facility in Braeside, Victoria, where it produces oral dose products including softgels, Vegicaps capsules, and OptiShell capsules, for supply across Asia Pacific.
Catalent Asia Pacific president Mark Bisset said: "This acquisition complements our industry-leading oral dosage form development and manufacturing capabilities with a broader range of packaging options, from bulk supply to finished packs.
"Catalent has made substantial recent investments in Asia Pacific with a new facility in China, and last year we celebrated our 40th year in Japan with a new laboratory and the build-out of more manufacturing capacity.
"This latest investment is in response to strong, local market demand for both pharmaceutical, over-the-counter (OTC) and Complementary Medicine products."
The company will continue to operate as Pharmapak Technologies retaining its 100 employees including the leadership team at its existing facility in Dee Why, New South Wales.
Capabilities of Pharmapak include primary and secondary packaging of oral pharmaceutical dose forms including blisters, bottles and a wide range of tertiary packaging services.